Sales and Marketing

News

Novo Nordisk has turned to pricing as a means to shore up its position in the increasingly competitive market for GLP-1 agonist therapies in the US.

News

AZ reports strong financial results for 2025, and provides a first peek at the data for its oral GLP-1 contender elecoglipron.

News

Three years after its first launch in the US, there are signs that Biogen and Eisai's Alzheimer's Leqembi therapy is gathering sales momentum.

News

Eli Lilly is predicting strong sales and profit growth in 2026, seemingly shrugging off the pricing pressure that weighed heavily on Novo Nordisk.

News

Luke Miels' first financial results since taking over as chief executive of GSK revealed a jump in sales and profits.

News

Squeezed by "unprecedented" pricing pressures, Novo Nordisk has forecast a decline in revenues this year.